Loading...
Header Logo
Keywords
Last Name
Institution

IMAD SHUREIQI

TitleAssociate Professor
InstitutionMD Anderson
DepartmentGI Medical Oncology
vCardDownload vCard

    Collapse ORNG Applications 
    Collapse Verify Publications

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Jácome AA, Kee B, Fogelman D, Dasari A, Shureiqi I, Raghav K, Morris V, Johnson B, Overman M, Wolff R, Kopetz S, Rogers J, Ahmed SU, Mehdizadeh A, Rothschild N, Eng C. FOLFOXIRI Versus Doublet Regimens in Right-Sided Metastatic Colorectal Cancer: Focus on Subsequent Therapies and Impact on Overall Survival. Clin Colorectal Cancer. 2020 Jun 05. PMID: 32665092.
      View in: PubMed
    2. Advani SM, Shi Q, Overman MJ, Loree JM, Lam M, Morris V, Shureiqi I, Kee B, Dasari A, Vilar E, Sarshekeh AM, Lin HK, Manuel S, Hamilton S, Raghav K, Maru D, Kopetz S, Wang XS. Patient-reported Symptom Outcomes and Microsatellite Instability in Patients With Metastatic Colorectal Cancer. Clin Colorectal Cancer. 2020 Mar; 19(1):48-56.e2. PMID: 32008976.
      View in: PubMed
    3. Korphaisarn K, Morris V, Davis JS, Overman MJ, Fogelman DR, Kee BK, Dasari A, Raghav KPS, Shureiqi I, Trupti M, Wolff RA, Eng C, Menter DG, Hamilton S, Kopetz S. Signet ring cell colorectal cancer: genomic insights into a rare subpopulation of colorectal adenocarcinoma. Br J Cancer. 2019 09; 121(6):505-510. PMID: 31406299.
      View in: PubMed
    4. Zuo X, Deguchi Y, Xu W, Liu Y, Li HS, Wei D, Tian R, Chen W, Xu M, Yang Y, Gao S, Jaoude JC, Liu F, Chrieki SP, Moussalli MJ, Gagea M, Sebastian MM, Zheng X, Tan D, Broaddus R, Wang J, Ajami NJ, Swennes AG, Watowich SS, Shureiqi I. PPARD and Interferon Gamma Promote Transformation of Gastric Progenitor Cells and Tumorigenesis in Mice. Gastroenterology. 2019 07; 157(1):163-178. PMID: 30885780.
      View in: PubMed
    5. Liu Y, Deguchi Y, Tian R, Wei D, Wu L, Chen W, Xu W, Xu M, Liu F, Gao S, Jaoude JC, Chrieki SP, Moussalli MJ, Gagea M, Morris J, Broaddus RR, Zuo X, Shureiqi I. Pleiotropic Effects of PPARD Accelerate Colorectal Tumorigenesis, Progression, and Invasion. Cancer Res. 2019 03 01; 79(5):954-969. PMID: 30679176.
      View in: PubMed
    6. Liu Y, Colby JK, Zuo X, Jaoude J, Wei D, Shureiqi I. The Role of PPAR-d in Metabolism, Inflammation, and Cancer: Many Characters of a Critical Transcription Factor. Int J Mol Sci. 2018 Oct 26; 19(11). PMID: 30373124.
      View in: PubMed
    7. Wang L, Shureiqi I, Stroehlein JR, Wei D. Novel and emerging innate immune therapeutic targets for pancreatic cancer. Expert Opin Ther Targets. 2018 12; 22(12):977-981. PMID: 30332892.
      View in: PubMed
    8. Colby JK, Jaoude J, Liu F, Shureiqi I. Oxygenated lipid signaling in tumor-associated macrophages-focus on colon cancer. Cancer Metastasis Rev. 2018 09; 37(2-3):289-315. PMID: 29934822.
      View in: PubMed
    9. Shureiqi I. Molecular Predicators of Duodenal Familial Adenomatous Polyposis Chemoprevention: Do Chemopreventive Drugs Hit Their Presumed Molecular Targets? Cancer Prev Res (Phila). 2018 01; 11(1):1-3. PMID: 29263155.
      View in: PubMed
    10. Pereira AAL, Morelli MP, Overman M, Kee B, Fogelman D, Vilar E, Shureiqi I, Raghav K, Eng C, Manuel S, Crosby S, Wolff RA, Banks K, Lanman R, Talasaz A, Kopetz S, Morris V. Clinical utility of circulating cell-free DNA in advanced colorectal cancer. PLoS One. 2017; 12(8):e0183949. PMID: 28850629.
      View in: PubMed
    11. Korphaisarn K, Morris VK, Overman MJ, Fogelman DR, Kee BK, Raghav KPS, Manuel S, Shureiqi I, Wolff RA, Eng C, Menter D, Hamilton SR, Kopetz S, Dasari A. FBXW7 missense mutation: a novel negative prognostic factor in metastatic colorectal adenocarcinoma. Oncotarget. 2017 Jun 13; 8(24):39268-39279. PMID: 28424412.
      View in: PubMed
    12. Mehrvarz Sarshekeh A, Advani S, Overman MJ, Manyam G, Kee BK, Fogelman DR, Dasari A, Raghav K, Vilar E, Manuel S, Shureiqi I, Wolff RA, Patel KP, Luthra R, Shaw K, Eng C, Maru DM, Routbort MJ, Meric-Bernstam F, Kopetz S. Association of SMAD4 mutation with patient demographics, tumor characteristics, and clinical outcomes in colorectal cancer. PLoS One. 2017; 12(3):e0173345. PMID: 28267766.
      View in: PubMed
    13. Tian R, Zuo X, Jaoude J, Mao F, Colby J, Shureiqi I. ALOX15 as a suppressor of inflammation and cancer: Lost in the link. Prostaglandins Other Lipid Mediat. 2017 09; 132:77-83. PMID: 28089732.
      View in: PubMed
    14. Zuo X, Xu W, Xu M, Tian R, Moussalli MJ, Mao F, Zheng X, Wang J, Morris JS, Gagea M, Eng C, Kopetz S, Maru DM, Rashid A, Broaddus R, Wei D, Hung MC, Sood AK, Shureiqi I. Metastasis regulation by PPARD expression in cancer cells. JCI Insight. 2017 01 12; 2(1):e91419. PMID: 28097239.
      View in: PubMed
    15. Wu Y, Fang B, Yang XQ, Wang L, Chen D, Krasnykh V, Carter BZ, Morris JS, Shureiqi I. Therapeutic Molecular Targetingof 15-Lipoxygenase-1 in Colon Cancer. Mol Ther. 2008 May; 16(5):886-892. PMID: 28178489.
      View in: PubMed
    16. Hong DS, Morris VK, El Osta B, Sorokin AV, Janku F, Fu S, Overman MJ, Piha-Paul S, Subbiah V, Kee B, Tsimberidou AM, Fogelman D, Bellido J, Shureiqi I, Huang H, Atkins J, Tarcic G, Sommer N, Lanman R, Meric-Bernstam F, Kopetz S. Phase IB Study of Vemurafenib in Combination with Irinotecan and Cetuximab in Patients with Metastatic Colorectal Cancer with BRAFV600E Mutation. Cancer Discov. 2016 12; 6(12):1352-1365. PMID: 27729313.
      View in: PubMed
    17. Overman MJ, Morris V, Kee B, Fogelman D, Xiao L, Eng C, Dasari A, Shroff R, Mazard T, Shaw K, Vilar E, Raghav K, Shureiqi I, Liang L, Mills GB, Wolff RA, Hamilton S, Meric-Bernstam F, Abbruzzese J, Morris J, Maru D, Kopetz S. Utility of a molecular prescreening program in advanced colorectal cancer for enrollment on biomarker-selected clinical trials. Ann Oncol. 2016 06; 27(6):1068-74. PMID: 27045102.
      View in: PubMed
    18. Sak ME, Alanbay I, Rodriguez A, Gokaslan T, Borahay M, Shureiqi I, Kilic GS. The role of 15-lipoxygenase-1 expression and its potential role in the pathogenesis of endometrial hyperplasia and endometrial adenocarcinomas. Eur J Gynaecol Oncol. 2016; 37(1):36-40. PMID: 27048107.
      View in: PubMed
    19. Ford NA, Rossi EL, Barnett K, Yang P, Bowers LW, Hidaka BH, Kimler BF, Carlson SE, Shureiqi I, deGraffenried LA, Fabian CJ, Hursting SD. Omega-3-Acid Ethyl Esters Block the Protumorigenic Effects of Obesity in Mouse Models of Postmenopausal Basal-like and Claudin-Low Breast Cancer. Cancer Prev Res (Phila). 2015 Sep; 8(9):796-806. PMID: 26100521.
      View in: PubMed
    20. Reddy SM, Kopetz S, Morris J, Parikh N, Qiao W, Overman MJ, Fogelman D, Shureiqi I, Jacobs C, Malik Z, Jimenez CA, Wolff RA, Abbruzzese JL, Gallick G, Eng C. Phase II study of saracatinib (AZD0530) in patients with previously treated metastatic colorectal cancer. Invest New Drugs. 2015 Aug; 33(4):977-84. PMID: 26062928.
      View in: PubMed
    21. Mao F, Xu M, Zuo X, Yu J, Xu W, Moussalli MJ, Elias E, Li HS, Watowich SS, Shureiqi I. 15-Lipoxygenase-1 suppression of colitis-associated colon cancer through inhibition of the IL-6/STAT3 signaling pathway. FASEB J. 2015 Jun; 29(6):2359-70. PMID: 25713055.
      View in: PubMed
    22. Bolonesi RM, Rogers JE, Shureiqi I. A case report--treatment of metastatic colorectal cancer in a patient on hemodialysis. J Gastrointest Cancer. 2014 Dec; 45 Suppl 1:161-5. PMID: 24756833.
      View in: PubMed
    23. Zuo X, Xu M, Yu J, Wu Y, Moussalli MJ, Manyam GC, Lee SI, Liang S, Gagea M, Morris JS, Broaddus RR, Shureiqi I. Potentiation of colon cancer susceptibility in mice by colonic epithelial PPAR-d/ß overexpression. J Natl Cancer Inst. 2014 Apr; 106(4):dju052. PMID: 24681603.
      View in: PubMed
    24. Wu Y, Mao F, Zuo X, Moussalli MJ, Elias E, Xu W, Shureiqi I. 15-LOX-1 suppression of hypoxia-induced metastatic phenotype and HIF-1a expression in human colon cancer cells. Cancer Med. 2014 Jun; 3(3):472-84. PMID: 24634093.
      View in: PubMed
    25. Tahara T, Yamamoto E, Suzuki H, Maruyama R, Chung W, Garriga J, Jelinek J, Yamano HO, Sugai T, An B, Shureiqi I, Toyota M, Kondo Y, Estécio MR, Issa JP. Fusobacterium in colonic flora and molecular features of colorectal carcinoma. Cancer Res. 2014 Mar 01; 74(5):1311-8. PMID: 24385213.
      View in: PubMed
    26. Das P, Eng C, Rodriguez-Bigas MA, Chang GJ, Skibber JM, You YN, Maru DM, Munsell MF, Clemons MV, Kopetz SE, Garrett CR, Shureiqi I, Delclos ME, Krishnan S, Crane CH. Preoperative radiation therapy with concurrent capecitabine, bevacizumab, and erlotinib for rectal cancer: a phase 1 trial. Int J Radiat Oncol Biol Phys. 2014 Feb 01; 88(2):301-5. PMID: 24315563.
      View in: PubMed
    27. Bailey AM, Zhan L, Maru D, Shureiqi I, Pickering CR, Kiriakova G, Izzo J, He N, Wei C, Baladandayuthapani V, Liang H, Kopetz S, Powis G, Guo GL. FXR silencing in human colon cancer by DNA methylation and KRAS signaling. Am J Physiol Gastrointest Liver Physiol. 2014 Jan 01; 306(1):G48-58. PMID: 24177031.
      View in: PubMed
    28. Ling H, Spizzo R, Atlasi Y, Nicoloso M, Shimizu M, Redis RS, Nishida N, Gafà R, Song J, Guo Z, Ivan C, Barbarotto E, De Vries I, Zhang X, Ferracin M, Churchman M, van Galen JF, Beverloo BH, Shariati M, Haderk F, Estecio MR, Garcia-Manero G, Patijn GA, Gotley DC, Bhardwaj V, Shureiqi I, Sen S, Multani AS, Welsh J, Yamamoto K, Taniguchi I, Song MA, Gallinger S, Casey G, Thibodeau SN, Le Marchand L, Tiirikainen M, Mani SA, Zhang W, Davuluri RV, Mimori K, Mori M, Sieuwerts AM, Martens JW, Tomlinson I, Negrini M, Berindan-Neagoe I, Foekens JA, Hamilton SR, Lanza G, Kopetz S, Fodde R, Calin GA. CCAT2, a novel noncoding RNA mapping to 8q24, underlies metastatic progression and chromosomal instability in colon cancer. Genome Res. 2013 Sep; 23(9):1446-61. PMID: 23796952.
      View in: PubMed
    29. Lynch PM, Morris JS, Ross WA, Rodriguez-Bigas MA, Posadas J, Khalaf R, Weber DM, Sepeda VO, Levin B, Shureiqi I. Global quantitative assessment of the colorectal polyp burden in familial adenomatous polyposis by using a web-based tool. Gastrointest Endosc. 2013 Mar; 77(3):455-63. PMID: 23332604.
      View in: PubMed
    30. Yang P, Cartwright C, Efuet E, Hamilton SR, Wistuba II, Menter D, Addington C, Shureiqi I, Newman RA. Cellular location and expression of Na+, K+ -ATPase a subunits affect the anti-proliferative activity of oleandrin. Mol Carcinog. 2014 Apr; 53(4):253-63. PMID: 23073998.
      View in: PubMed
    31. Xu M, Zuo X, Shureiqi I. Targeting peroxisome proliferator-activated receptor-ß/d in colon cancer: how to aim? Biochem Pharmacol. 2013 Mar 01; 85(5):607-611. PMID: 23041232.
      View in: PubMed
    32. Zuo X, Shureiqi I. Eicosanoid profiling in colon cancer: emergence of a pattern. Prostaglandins Other Lipid Mediat. 2013 Jul-Aug; 104-105:139-43. PMID: 22960430.
      View in: PubMed
    33. Yang P, Cartwright CA, Li J, Wen S, Prokhorova IN, Shureiqi I, Troncoso P, Navone NM, Newman RA, Kim J. Arachidonic acid metabolism in human prostate cancer. Int J Oncol. 2012 Oct; 41(4):1495-503. PMID: 22895552.
      View in: PubMed
    34. Zuo X, Peng Z, Wu Y, Moussalli MJ, Yang XL, Wang Y, Parker-Thornburg J, Morris JS, Broaddus RR, Fischer SM, Shureiqi I. Effects of gut-targeted 15-LOX-1 transgene expression on colonic tumorigenesis in mice. J Natl Cancer Inst. 2012 May 02; 104(9):709-16. PMID: 22472308.
      View in: PubMed
    35. Il Lee S, Zuo X, Shureiqi I. 15-Lipoxygenase-1 as a tumor suppressor gene in colon cancer: is the verdict in? Cancer Metastasis Rev. 2011 Dec; 30(3-4):481-91. PMID: 22037943.
      View in: PubMed
    36. Moussalli MJ, Wu Y, Zuo X, Yang XL, Wistuba II, Raso MG, Morris JS, Bowser JL, Minna JD, Lotan R, Shureiqi I. Mechanistic contribution of ubiquitous 15-lipoxygenase-1 expression loss in cancer cells to terminal cell differentiation evasion. Cancer Prev Res (Phila). 2011 Dec; 4(12):1961-72. PMID: 21881028.
      View in: PubMed
    37. Shureiqi I, Baron JA. Curcumin chemoprevention: the long road to clinical translation. Cancer Prev Res (Phila). 2011 Mar; 4(3):296-8. PMID: 21372027.
      View in: PubMed
    38. Shureiqi I, Chen D, Day RS, Zuo X, Hochman FL, Ross WA, Cole RA, Moy O, Morris JS, Xiao L, Newman RA, Yang P, Lippman SM. Profiling lipoxygenase metabolism in specific steps of colorectal tumorigenesis. Cancer Prev Res (Phila). 2010 Jul; 3(7):829-38. PMID: 20570882.
      View in: PubMed
    39. Zuo X, Peng Z, Moussalli MJ, Morris JS, Broaddus RR, Fischer SM, Shureiqi I. Targeted genetic disruption of peroxisome proliferator-activated receptor-delta and colonic tumorigenesis. J Natl Cancer Inst. 2009 May 20; 101(10):762-7. PMID: 19436036.
      View in: PubMed
    40. Zuo X, Morris JS, Broaddus R, Shureiqi I. 15-LOX-1 transcription suppression through the NuRD complex in colon cancer cells. Oncogene. 2009 Mar 26; 28(12):1496-505. PMID: 19198625.
      View in: PubMed
    41. Zuo X, Morris JS, Shureiqi I. Chromatin modification requirements for 15-lipoxygenase-1 transcriptional reactivation in colon cancer cells. J Biol Chem. 2008 Nov 14; 283(46):31341-7. PMID: 18799463.
      View in: PubMed
    42. Kopetz S, Overman M, Chang DZ, Glover KY, Shureiqi I, Wolff RA, Abbruzzese JL, Eng C. Systematic survey of therapeutic trials for metastatic colorectal cancer: room for improvement in the critical pathway. J Clin Oncol. 2008 Apr 20; 26(12):2000-5. PMID: 18421052.
      View in: PubMed
    43. Wu Y, Fang B, Yang XQ, Wang L, Chen D, Krasnykh V, Carter BZ, Morris JS, Shureiqi I. Therapeutic molecular targeting of 15-lipoxygenase-1 in colon cancer. Mol Ther. 2008 May; 16(5):886-92. PMID: 18388920.
      View in: PubMed
    44. Zuo X, Shen L, Issa JP, Moy O, Morris JS, Lippman SM, Shureiqi I. 15-Lipoxygenase-1 transcriptional silencing by DNA methyltransferase-1 independently of DNA methylation. FASEB J. 2008 Jun; 22(6):1981-92. PMID: 18198215.
      View in: PubMed
    45. Shureiqi I, Zuo X, Broaddus R, Wu Y, Guan B, Morris JS, Lippman SM. The transcription factor GATA-6 is overexpressed in vivo and contributes to silencing 15-LOX-1 in vitro in human colon cancer. FASEB J. 2007 Mar; 21(3):743-53. PMID: 17167069.
      View in: PubMed
    46. Yang P, Chan D, Felix E, Madden T, Klein RD, Shureiqi I, Chen X, Dannenberg AJ, Newman RA. Determination of endogenous tissue inflammation profiles by LC/MS/MS: COX- and LOX-derived bioactive lipids. Prostaglandins Leukot Essent Fatty Acids. 2006 Dec; 75(6):385-95. PMID: 17011176.
      View in: PubMed
    47. Zuo X, Wu Y, Morris JS, Stimmel JB, Leesnitzer LM, Fischer SM, Lippman SM, Shureiqi I. Oxidative metabolism of linoleic acid modulates PPAR-beta/delta suppression of PPAR-gamma activity. Oncogene. 2006 Feb 23; 25(8):1225-41. PMID: 16288226.
      View in: PubMed
    48. Shureiqi I, Wu Y, Chen D, Yang XL, Guan B, Morris JS, Yang P, Newman RA, Broaddus R, Hamilton SR, Lynch P, Levin B, Fischer SM, Lippman SM. The critical role of 15-lipoxygenase-1 in colorectal epithelial cell terminal differentiation and tumorigenesis. Cancer Res. 2005 Dec 15; 65(24):11486-92. PMID: 16357157.
      View in: PubMed
    49. Deguchi A, Xing SW, Shureiqi I, Yang P, Newman RA, Lippman SM, Feinmark SJ, Oehlen B, Weinstein IB. Activation of protein kinase G up-regulates expression of 15-lipoxygenase-1 in human colon cancer cells. Cancer Res. 2005 Sep 15; 65(18):8442-7. PMID: 16166323.
      View in: PubMed
    50. Hsi LC, Xi X, Lotan R, Shureiqi I, Lippman SM. The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces apoptosis via induction of 15-lipoxygenase-1 in colorectal cancer cells. Cancer Res. 2004 Dec 01; 64(23):8778-81. PMID: 15574791.
      View in: PubMed
    51. Duffield-Lillico AJ, Shureiqi I, Lippman SM. Can selenium prevent colorectal cancer? A signpost from epidemiology. J Natl Cancer Inst. 2004 Nov 17; 96(22):1645-7. PMID: 15547171.
      View in: PubMed
    52. Shureiqi I, Jiang W, Zuo X, Wu Y, Stimmel JB, Leesnitzer LM, Morris JS, Fan HZ, Fischer SM, Lippman SM. The 15-lipoxygenase-1 product 13-S-hydroxyoctadecadienoic acid down-regulates PPAR-delta to induce apoptosis in colorectal cancer cells. Proc Natl Acad Sci U S A. 2003 Aug 19; 100(17):9968-73. PMID: 12909723.
      View in: PubMed
    53. Winer I, Normolle DP, Shureiqi I, Sondak VK, Johnson T, Su L, Brenner DE. Expression of 12-lipoxygenase as a biomarker for melanoma carcinogenesis. Melanoma Res. 2002 Oct; 12(5):429-34. PMID: 12394183.
      View in: PubMed
    54. Shureiqi I, Jiang W, Fischer SM, Xu X, Chen D, Lee JJ, Lotan R, Lippman SM. GATA-6 transcriptional regulation of 15-lipoxygenase-1 during NSAID-induced apoptosis in colorectal cancer cells. Cancer Res. 2002 Feb 15; 62(4):1178-83. PMID: 11861401.
      View in: PubMed
    55. Shureiqi I, Cantor SB, Lippman SM, Brenner DE, Chernew ME, Fendrick AM. Clinical and economic impact of multiple gated acquisition scan monitoring during anthracycline therapy. Br J Cancer. 2002 Jan 21; 86(2):226-32. PMID: 11870511.
      View in: PubMed
    56. McGinn CJ, Zalupski MM, Shureiqi I, Robertson JM, Eckhauser FE, Smith DC, Brown D, Hejna G, Strawderman M, Normolle D, Lawrence TS. Phase I trial of radiation dose escalation with concurrent weekly full-dose gemcitabine in patients with advanced pancreatic cancer. J Clin Oncol. 2001 Nov 15; 19(22):4202-8. PMID: 11709563.
      View in: PubMed
    57. Shureiqi I, Lippman SM. Lipoxygenase modulation to reverse carcinogenesis. Cancer Res. 2001 Sep 01; 61(17):6307-12. PMID: 11522616.
      View in: PubMed
    58. Shureiqi I, Cooksley CD, Morris J, Soliman AS, Levin B, Lippman SM. Effect of age on risk of second primary colorectal cancer. J Natl Cancer Inst. 2001 Aug 15; 93(16):1264-6. PMID: 11504772.
      View in: PubMed
    59. Shureiqi I, Xu X, Chen D, Lotan R, Morris JS, Fischer SM, Lippman SM. Nonsteroidal anti-inflammatory drugs induce apoptosis in esophageal cancer cells by restoring 15-lipoxygenase-1 expression. Cancer Res. 2001 Jun 15; 61(12):4879-84. PMID: 11406566.
      View in: PubMed
    60. Krishnan K, Ruffin MT, Normolle D, Shureiqi I, Burney K, Bailey J, Peters-Golden M, Rock CL, Boland CR, Brenner DE. Colonic mucosal prostaglandin E2 and cyclooxygenase expression before and after low aspirin doses in subjects at high risk or at normal risk for colorectal cancer. Cancer Epidemiol Biomarkers Prev. 2001 May; 10(5):447-53. PMID: 11352853.
      View in: PubMed
    61. Shureiqi I, Chen D, Lotan R, Yang P, Newman RA, Fischer SM, Lippman SM. 15-Lipoxygenase-1 mediates nonsteroidal anti-inflammatory drug-induced apoptosis independently of cyclooxygenase-2 in colon cancer cells. Cancer Res. 2000 Dec 15; 60(24):6846-50. PMID: 11156377.
      View in: PubMed
    62. Shureiqi I, Chen D, Lee JJ, Yang P, Newman RA, Brenner DE, Lotan R, Fischer SM, Lippman SM. 15-LOX-1: a novel molecular target of nonsteroidal anti-inflammatory drug-induced apoptosis in colorectal cancer cells. J Natl Cancer Inst. 2000 Jul 19; 92(14):1136-42. PMID: 10904086.
      View in: PubMed
    63. Shureiqi I, Reddy P, Brenner DE. Chemoprevention: general perspective. Crit Rev Oncol Hematol. 2000 Mar; 33(3):157-67. PMID: 10789490.
      View in: PubMed
    64. Shureiqi I, Wojno KJ, Poore JA, Reddy RG, Moussalli MJ, Spindler SA, Greenson JK, Normolle D, Hasan AA, Lawrence TS, Brenner DE. Decreased 13-S-hydroxyoctadecadienoic acid levels and 15-lipoxygenase-1 expression in human colon cancers. Carcinogenesis. 1999 Oct; 20(10):1985-95. PMID: 10506115.
      View in: PubMed
    65. Shureiqi I, Brenner DE. Chemoprevention of epithelial cancers. Curr Opin Oncol. 1999 Sep; 11(5):408-13. PMID: 10505781.
      View in: PubMed
    66. Phase II study of saracatinib (AZD0530) in patients with previously treated metastatic colorectal cancer. Investigational New Drugs.
    67. Omega-3-acid ethyl esters block the protumorigenic effects of obesity in mouse models of postmenopausal basal-like and claudin-low breast cancer. Cancer Prevention Research. 8:796-806.
    68. Phase IB study of vemurafenib in combination with irinotecan and cetuximab in patients with metastatic colorectal cancer with BRAFV600E mutation. Cancer Discovery. 6:1352-1365.
    69. ALOX15 as a suppressor of inflammation and cancer. Prostaglandins and Other Lipid Mediators.
    70. Utility of a molecular prescreening program in advanced colorectal cancer for enrollment on biomarker-selected clinical trials. Annals of Oncology. 27:1068-1074.
    SHUREIQI's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    _
    Co-Authors Expand Description
    _
    Similar People Expand Description
    _
    Same Department Expand Description